scholarly journals Cysteamine bitartrate delayed‐release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open‐label study of treatment‐naïve patients <6 years of age with nephropathic cystinosis

JIMD Reports ◽  
2021 ◽  
Author(s):  
Maria Helena Vaisbich ◽  
Juliana Caires Ferreira ◽  
Heather Price ◽  
Kyleen D. Young ◽  
Saba Sile ◽  
...  
Keyword(s):  
Nephropathic Cystinosis ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Delayed Release ◽  
Treatment Naïve ◽  
Kidney Health

scholarly journals Open-label study of maraviroc+lamivudine/zidovudine in treatment-naïve adults infected with HIV-1, predominantly subtype A, by population genotyping

2012 ◽  
Vol 15 (6(Suppl 4)) ◽  
Author(s):  
S Portsmouth ◽  
S Valluri ◽  
C Craig ◽  
M Lewis ◽  
V Pokrovsky ◽  
...  
Keyword(s):  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Treatment Naïve ◽  
Subtype A ◽  
Hiv 1

scholarly journals Nocturnal Asthma: Proof-of-Concept Open-Label Study with Delayed-Release Prednisone

2015 ◽  
Vol 1 (1) ◽  
pp. 43-52 ◽  
Author(s):  
Loubna Alavoine ◽  
Camile Taillé ◽  
Julie Ball ◽  
Christine Knauer ◽  
Stephan Witte ◽  
...  
Keyword(s):  
Proof Of Concept ◽  
Open Label ◽  
Nocturnal Asthma ◽  
Open Label Study ◽  
Label Study ◽  
Delayed Release

Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients

2017 ◽  
Vol 112 (12) ◽  
pp. 1824-1831 ◽  
Author(s):  
Mindie H Nguyen ◽  
Huy Trinh ◽  
Son Do ◽  
Thuan Nguyen ◽  
Pauline Nguyen ◽  
...  
Keyword(s):  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Treatment Naïve

scholarly journals Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC

2018 ◽  
Vol 29 ◽  
pp. viii740 ◽  
Author(s):  
C. Zhou ◽  
Y. Lu ◽  
S.-W. Kim ◽  
T. Reungwetwattana ◽  
J. Zhou ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Phase Iii ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Asian Patients ◽  
Treatment Naïve

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 9094-9094 ◽  
Author(s):  
Dong-Wan Kim ◽  
Daniel Shao-Weng Tan ◽  
Santiago Ponce Aix ◽  
Lecia V. Sequist ◽  
Egbert F. Smit ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Treatment Naïve ◽  
Egfr Mutant ◽  
Preliminary Phase

Phase 3, Multicenter Open‐Label study to investigate the efficacy of elbasvir and grazoprevir fixed‐dose combination for 8 weeks in treatment‐naïve, HCV GT1b‐infected patients, with non‐severe fibrosis

2020 ◽  
Vol 40 (8) ◽  
pp. 1853-1859 ◽  
Author(s):  
Armand Abergel ◽  
Tarik Asselah ◽  
Arianne Mallat ◽  
Brigitte Chanteranne ◽  
Frederic Faure ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Study ◽  
Label Study ◽  
Treatment Naïve ◽  
Dose Combination ◽  
Severe Fibrosis

scholarly journals Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

2017 ◽  
Vol 65 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Jordan J Feld ◽  
Alnoor Ramji ◽  
Stephen D Shafran ◽  
Bernard Willems ◽  
Paul Marotta ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Genotype 3 ◽  
Virus Genotype ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Treatment Naïve
Sign in / Sign up

Export Citation Format

Share Document